# Single-Cell RNA Sequencing Reveals the Cellular and Molecular Differences Between Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma

**Authors:** Timur I. Fetisov, Alexander V. Ikonnikov, Elena E. Kopantseva, Polina A. Shtompel, Sofya A. Khazanova, Ekaterina S. Trapeznikova, Victoria Y. Zinovieva, Svetlana N. Zuevskaya, Anastasia A. Tararykova, Beniamin Yu. Bokhyan, Gennady A. Belitsky, Ekaterina A. Lesovaya, Marianna G. Yakubovskaya, Evgeny V. Denisov, Kirill I. Kirsanov

PMC · DOI: 10.3390/medsci14010077 · Medical Sciences · 2026-02-10

## TL;DR

This study uses single-cell RNA sequencing to uncover cellular and molecular differences between two aggressive sarcoma types, which could help improve their diagnosis and treatment.

## Contribution

The study reveals novel transcriptomic and intercellular interaction differences between myxofibrosarcoma and undifferentiated pleomorphic sarcoma using single-cell RNA sequencing.

## Key findings

- Lymphoid cell proportions, particularly cytotoxic CD8+ T cells, differ between myxofibrosarcoma and undifferentiated pleomorphic sarcoma.
- UPS cancer cells show high extracellular matrix pathway activity, while MXF cells exhibit active growth factor and angiogenesis pathways.
- Distinct ligand–receptor interactions between cancer cells and the microenvironment were identified in UPS and MXF.

## Abstract

Objective: Myxofibrosarcoma (MXF) and undifferentiated pleomorphic sarcoma (UPS) are common and aggressive subtypes of cancer differing by clinical characteristics and prognosis; however, their differential diagnosis is difficult. Elucidation of cellular and transcriptomic discrepancies between these diseases that could improve their identification was the aim of our study. Methods: We applied single-cell RNA sequencing to compare MXF and UPS by tumor cell clusters and cell–cell ligand–receptor interactions, using five tumor samples of both subtypes. Results: We identify nine major cell types in all tumors analyzed. Any significant differences in their proportions between MXF and UPS were not found. Further reclusterization of lymphoid cells showed that cytotoxic CD8+ T cell proportion was higher in the MXF samples. In UPS cancer cells, the pathways maintaining extracellular matrix components (including collagens, proteoglycans, and other proteins) were highly active, while MXF cells were characterized by high activity of growth factors and angiogenesis pathways. The ligand–receptor interactions between cancer cells and the microenvironment differed significantly between MXF and UPS. In UPS, CD80 of dendritic cells and macrophages prominently interacted with T cell co-inhibitory CTLA-4 receptors, whereas the activating CD80-CD28 interaction was predominant in MXF. Moreover, in UPS, CD44 and integrins of cytotoxic CD8+ T cells prominently interacted with COL1A1/2, while in MXF CD44, interaction with FN1, COL6A1, and LAMC1 prevailed. Conclusions: Differences were identified between UPS and MFS in the composition of lymphoid cell populations and in the intercellular interactions. This proposes deeper understanding of the biological differences between these sarcoma subtypes and may be important for the development of new therapeutic approaches, although further validation of the findings is required.

## Linked entities

- **Genes:** CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493], CD80 (CD80 molecule) [NCBI Gene 941], CD28 (CD28 molecule) [NCBI Gene 940], CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960], COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277], COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278], FN1 (fibronectin 1) [NCBI Gene 2335], COL6A1 (collagen type VI alpha 1 chain) [NCBI Gene 1291], LAMC1 (laminin subunit gamma 1) [NCBI Gene 3915]
- **Proteins:** COL1A1 (collagen type I alpha 1 chain), COL1A2 (collagen type I alpha 2 chain), FN1 (fibronectin 1), COL6A1 (collagen type VI alpha 1 chain), LAMC1 (laminin subunit gamma 1)
- **Diseases:** myxofibrosarcoma (MONDO:0019202), undifferentiated pleomorphic sarcoma (MONDO:0002142)

## Full-text entities

- **Genes:** CD99 (CD99 molecule (Xg blood group)) [NCBI Gene 4267] {aka HBA71, MIC2, MIC2X, MIC2Y, MSK5X}, CTSK (cathepsin K) [NCBI Gene 1513] {aka CTS02, CTSO, CTSO1, CTSO2, PKND, PYCD}, IBSP (integrin binding sialoprotein) [NCBI Gene 3381] {aka BNSP, BSP, BSP II, BSP-II, SP-II}, MKI67 (marker of proliferation Ki-67) [NCBI Gene 4288] {aka KIA, MIB-, MIB-1, PPP1R105}, COL12A1 (collagen type XII alpha 1 chain) [NCBI Gene 1303] {aka BA209D8.1, BTHLM2, COL12A1L, DJ234P15.1, EDSMYP, UCMD2}, EFHD2 (EF-hand domain family member D2) [NCBI Gene 79180] {aka SWS1}, MMP14 (matrix metallopeptidase 14) [NCBI Gene 4323] {aka MMP-14, MMP-X1, MT-MMP, MT-MMP 1, MT1-MMP, MT1MMP}, KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914] {aka CD314, D12S2489E, KLR, NKG2-D, NKG2D}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, ADGRG1 (adhesion G protein-coupled receptor G1) [NCBI Gene 9289] {aka BFPP, BPPR, CDCBM14B, CDCBM15A, GPR56, TM7LN4}, COL6A1 (collagen type VI alpha 1 chain) [NCBI Gene 1291] {aka BTHLM1, BTHLM1A, OPLL, UCHMD1, UCHMD1A}, CD2 (CD2 molecule) [NCBI Gene 914] {aka LFA-2, SRBC, T11}, NCR1 (natural cytotoxicity triggering receptor 1) [NCBI Gene 9437] {aka CD335, LY94, NK-p46, NKP46}, JCHAIN (joining chain of multimeric IgA and IgM) [NCBI Gene 3512] {aka IGCJ, IGJ, JCH}, HSPA1A (heat shock protein family A (Hsp70) member 1A) [NCBI Gene 3303] {aka HEL-S-103, HSP70, HSP70-1, HSP70-1A, HSP70-2, HSP70.1}, FLT1 (fms related receptor tyrosine kinase 1) [NCBI Gene 2321] {aka FLT, FLT-1, VEGFR-1, VEGFR1}, TNFSF13B (TNF superfamily member 13b) [NCBI Gene 10673] {aka BAFF, BLYS, CD257, TALL-1, TALL1, THANK}, CTSZ (cathepsin Z) [NCBI Gene 1522] {aka CTSX}, CA2 (carbonic anhydrase 2) [NCBI Gene 760] {aka CA-II, CAC, CAII, Car2, HEL-76, HEL-S-282}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, DDIT3 (DNA damage inducible transcript 3) [NCBI Gene 1649] {aka AltDDIT3, C/EBPzeta, CEBPZ, CHOP, CHOP-10, CHOP10}, COL8A2 (collagen type VIII alpha 2 chain) [NCBI Gene 1296] {aka FECD, FECD1, PPCD, PPCD2}, RSAD2 (radical S-adenosyl methionine domain containing 2) [NCBI Gene 91543] {aka SAND, cig33, cig5, vig1}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, ERRFI1 (ERBB receptor feedback inhibitor 1) [NCBI Gene 54206] {aka GENE-33, MIG-6, MIG6, RALT}, OAS2 (2'-5'-oligoadenylate synthetase 2) [NCBI Gene 4939] {aka AIAISD2}, CTSB (cathepsin B) [NCBI Gene 1508] {aka APPS, CPSB, KWE, RECEUP}, PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) [NCBI Gene 5352] {aka BRKS2, LH2, TLH}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, C1QB (complement C1q B chain) [NCBI Gene 713] {aka C1QD2}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, MZB1 (marginal zone B and B1 cell specific protein) [NCBI Gene 51237] {aka MEDA-7, PACAP, pERp1}, TOP2A (DNA topoisomerase II alpha) [NCBI Gene 7153] {aka TOP2, TOP2alpha, TOPIIA, TP2A}, IER2 (immediate early response 2) [NCBI Gene 9592] {aka CHX1, ETR101}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, DERL3 (derlin 3) [NCBI Gene 91319] {aka C22orf14, IZP6, LLN2, derlin-3}, NKG7 (natural killer cell granule protein 7) [NCBI Gene 4818] {aka GIG1, GMP-17, p15-TIA-1}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, VCAN (versican) [NCBI Gene 1462] {aka CSPG2, ERVR, GHAP, PG-M, WGN, WGN1}, RSRP1 (arginine and serine rich protein 1) [NCBI Gene 57035] {aka C1orf63, NPD014}, SLC3A2 (solute carrier family 3 member 2) [NCBI Gene 6520] {aka 4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1}, ATRX (ATRX chromatin remodeler) [NCBI Gene 546] {aka JMS, MRX52, RAD54, RAD54L, XH2, XNP}, PDCD1LG2 (programmed cell death 1 ligand 2) [NCBI Gene 80380] {aka B7DC, Btdc, CD273, PD-L2, PDCD1L2, PDL2}, CLEC10A (C-type lectin domain containing 10A) [NCBI Gene 10462] {aka CD301, CLECSF13, CLECSF14, DC-ASGPR, HML, HML2}, SELENOP (selenoprotein P) [NCBI Gene 6414] {aka SELP, SEPP, SEPP1, SeP}, NGF (nerve growth factor) [NCBI Gene 4803] {aka Beta-NGF, HSAN5, NGFB}, LYST (lysosomal trafficking regulator) [NCBI Gene 1130] {aka CHS, CHS1, Mauve}, C1QA (complement C1q A chain) [NCBI Gene 712] {aka C1QD1}, ARHGEF2 (Rho/Rac guanine nucleotide exchange factor 2) [NCBI Gene 9181] {aka GEF, GEF-H1, GEFH1, LFP40, Lfc, NEDMHM}, GZMH (granzyme H) [NCBI Gene 2999] {aka CCP-X, CGL-2, CSP-C, CTLA1, CTSGL2}, Hmbs (hydroxymethylbilane synthase) [NCBI Gene 15288] {aka PBGD, Ups, Uros1}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, TRAC (T cell receptor alpha constant) [NCBI Gene 28755] {aka IMD7, TCRA, TRCA}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}, DCN (decorin) [NCBI Gene 1634] {aka CSCD, DSPG2, PG40, PGII, PGS2, SLRR1B}, H1-5 (H1.5 linker histone, cluster member) [NCBI Gene 3009] {aka H1, H1.5, H1B, H1F5, H1s-3, HIST1H1B}
- **Diseases:** immunodeficiency (MESH:D007153), metastasis (MESH:D009362), injury to (MESH:D014947), UPS (MESH:D002277), Cancer (MESH:D009369), MFS (MESH:D008382), hypoxia (MESH:D000860), pleomorphic sarcomas (MESH:D012509)
- **Chemicals:** hematoxylin (MESH:D006416), glycerol (MESH:D005990), paraffin (MESH:D010232), adenosine (MESH:D000241), propidium iodide (MESH:D011419), acridine orange (MESH:D000165), formalin (MESH:D005557), glutamate (MESH:D018698), calcitriol (MESH:D002117), PBS (MESH:D007854), eosin (MESH:D004801)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232), LFC 1 — Felis catus (Cat), Undefined cell line type (CVCL_S342), MXF — Homo sapiens (Human), Myxofibrosarcoma, Cancer cell line (CVCL_T030)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12922028/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12922028/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12922028/full.md

---
Source: https://tomesphere.com/paper/PMC12922028